Check out our psoriatic arthritis coverage from #EULAR2021. Head to RheumNow for full EULAR coverage. https://t.co/NzB2e2Vfwb

• https://bit.ly/3vQajub

RheumNow’s expanded coverage of the #EULAR2021 meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its Faculty.

What about musculoskeletal #pain in PsO patients? Results of a nationwide Danish survey #POS0149 that shed light into unadressed reduced quality of life and risk to move towards #PsA #EULAR2021 @RheumNow https://t.co/JQnHSvtpHm

Data from the COSMOS study showed that 44.4% of patients who received #guselkumab versus 19.8% of patients who received placebo achieved a ≥20% improvement at week 24. #psoriaticarthritis https://t.co/S3xnFSQDaJ

• Improved Psoriatic Arthritis Outcomes in Phase 3b Guselkinumab Trial

PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate) https://t.co/sUXTXDXrFh

• PROs in Spa and PSA: Dr. Rachel Tate | RheumNow

An original way of differentiating RA from PsA! The shape of the second MCP in HR-pQCT is enough to train a neural network with high accuracy for recognition of -HC 94% -RA 84% -PsA 89% and an AUC of 91%. #EULAR2021 @RheumNow #OP0145 https://t.co/BrwFQpX310

Q-DAPSA (DAPSA + CRP), validated as a clinical measure of PsA disease activity in both practice & research from 5 centers in Berlin, 104 PsA pts. Let's get more studies to better understand the power of this measure. Poster #POS1069 #EULAR2021 @RheumNow https://t.co/X4UWGwH5i5 https://t.co/J7EpOjTjhe

• https://ard.bmj.com/content/80/Suppl_1/813

SPACING trial: possible to taper TNFi in AxSpA pts in LDA ⭐️Tapering of TNFi in axSpA resulted in 88% BASDAI<4 compared to 91.5% in unchanged group ⭐️adalimumab spaced out to q35 days Abs#OP0138 #EULAR2021 @RheumNow

PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate) https://t.co/sUXTXDXrFh

• https://bit.ly/3wSTLSo

Patients selected to maximise response & minimise adverse events in RA & PsA trials. What implications does this have when we interpret the data & try to apply in clinic? #EULAR2021 https://t.co/CocKlvjme4

Placebo response in PsA trials have more than doubled in last decade. Due to patient characteristics, patient expectations? Makes it very difficult to compare between trials #EULAR2021 https://t.co/XQk4hqrYN8

ERA & JPsA children & adolescents tx'ed w/ SEC, JUNIPERA 104wk data: longer time to flare vs PBO. NRI analysis: 87.2%, 83.7%, 67.4%, 38.4% and 24.4% achieved JIA ACR 30/50/70/90/100, respectively. No new safety signals. #EULAR2021 @RheumNow Abstract #LB004 https://t.co/reWawBWfqh https://t.co/9gzKKU1xrm

• http://ow.ly/TMbx50F1XrE

Moysidou et al reviewed pubmed registries/longitudinal cohort studies in PsA. 27 registries, totaling 30 countries (67% European, 26% N. American) Africa not represented. This is a call to arms for global PsA pts! #EULAR2021 @RheumNow Poster #POS1078 https://t.co/rsQYR6NFNT https://t.co/MU3FVXuRxS

• http://ow.ly/gkVw50F1qW0